CA-MATRIXX-SOFTWARE,-INC
16.6.2020 15:02:10 CEST | Business Wire | Press release
MATRIXX Software , the global leader in 5G digital commerce solutions for communication service providers (CSPs), today announced the appointment of five strategic advisors with deep experience in building high growth telecom technology companies. These industry veterans will help MATRIXX develop strategies to further expand its leadership in powering 5G deployments for telecom operators worldwide.
Global leaders such as Vodafone, Swisscom, Verizon and Orange rely on MATRIXX for cloud native digital commerce solutions to radically increase operational agility, grow customer engagement and compete at web scale. The need for CSPs to compete at web scale has never been stronger as the rapid emergence of 5G is ushering in new business and operating models for operators and their enterprise customers.
“5G will support a new category of services for the enterprise market that most CSPs will be ill-equipped to effectively monetize using their existing charging systems,” explained John Abraham, Principal Analyst at Analysys Mason, “In the short to medium term, CSPs will invest in new convergent charging platforms, shifting away from complex and expensive-to-maintain monolithic frameworks. Cloud-native compliant, configurable, standards-based products that deliver exceptional architectural agility will become a key consideration in how CSPs procure systems in the future.”
As the only solution provider committed to delivering a configurable out of the box product, MATRIXX has emerged as the disruptor in the BSS and Charging markets. MATRIXX enters the 5G era powered by an impressive Compound Annual Growth Rate (CAGR) in Annual Contract Value (ACV) of more than 40% over the last four years as well as 100% customer retention. MATRIXX’s continued success in the market has attracted the talent of new advisors to further the Company's operational evolution and brand leadership.
“These five individuals bring exceptional depth and breadth to an already world-class team. Their expertise spans successful startups, CSPs and established networking companies,” said Glo Gordon, CEO MATRIXX Software. “As we enter into our hyper-growth phase, each will contribute a wealth of knowledge and experience to support MATRIXX’s scale.”
She continued, “Demand for our digital commerce solution has never been higher. Network teams deploying 5G know that what has worked in the past will not work in the future. Competitive dynamics, new enterprise opportunities and network agility are exponentially higher with 5G and that is why CSPs are choosing MATRIXX as their charging system partner. It’s an incredible time for us and I’m delighted that they have chosen to join us on our journey.”
Strategic Advisory Board
MATRIXX is excited to welcome the following to its strategic advisory board:
- Hassan Ahmed – Founder, Former CEO and Chairman of Affirmed Networks, recently acquired by Microsoft. Prior to Affirmed, Hassan served as Chairman and CEO of Sonus Networks (Nasdaq:SONS). Before Sonus, he was EVP and GM of the Core Switching division of Ascend Communications (Nasdaq: ASND) and VP Engineering and Chief Technology Officer of Cascade Communications (Nasdaq: CSCC). Hassan has also held key leadership positions at Motorola and Analog Devices.
- Daniel Collins – Co-Founder and CTO of Jasper Technologies and former CTO of Cisco IoT Business Unit after Cisco acquired Jasper in 2016 for $1.4B. Daniel is an experienced leader and author in the telecommunications space. Prior to Jasper, Daniel held senior positions with Alcatel, TeleworX and Ericsson and was instrumental in successfully launching new, category-defining technologies globally, including 3G and the Internet of Things.
- Heinz Herren – Former CTO, CIO and current Executive Board Member of Swisscom. Heinz has also lent his expertise to many well-known companies by participating on their Board of Directors or Investment Committees, including Cablex Ltd, Swisscom Broadcast, Park Innovaare Ltd., Swiss Innovation, tiko Energy Solutions, and Credit Suisse.
- Cliff Johnson – Former Senior Vice President of Jasper Technologies and Vice President Global IoT Service Operations at Cisco after Jasper was acquired in 2016. Prior to Jasper, Cliff was VP and Head of Customer Support Operations at Ericsson North America and also led operations for start-up Spatial Wireless acquired by Alcatel.
- Macario Namie – Currently Chief Marketing Officer at ASAPP. Previously Macario was head of Strategy for the Internet of Things business unit at Cisco and CMO and Vice President of Strategy for Jasper Technologies. A Silicon Valley veteran with significant startup experience, Macario has also held senior leadership positions at Webex, ePeople, and Lycos.
Global CSPs are choosing MATRIXX for their 5G deployments as they realize that new ways to compete will require new technology partners. Legacy architectures simply do not enable the agility necessary to meet dynamically changing market demand for new offers and services. MATRIXX’s digital commerce solution is built for the future:
- Cloud-native, patented technology designed for web scale
- Click, not code configurations to support CI/CD
- API-first architecture
Learn more about the agility that global CSPs have achieved at www.matrixx.com/customers .
About MATRIXX Software
MATRIXX Software provides next-generation, cloud native digital commerce solutions that transform how companies do business. Serving many of the world’s largest communications companies, IoT players and emerging digital service providers, MATRIXX is committed to delivering a modern commerce platform that easily scales to support global marketplaces and consumption-based services. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to reinvent themselves and succeed as digital leaders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005014/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
